Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead - PubMed (original) (raw)
Review
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead
Heiner Wedemeyer et al. Nat Rev Gastroenterol Hepatol. 2010 Jan.
Abstract
Hepatitis D is caused by infection with the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans. Hepatitis D occurs only in individuals positive for the HBV surface antigen (HBsAg) as HDV is a defective RNA viroid that requires HBsAg for transmission. At least eight different HDV genotypes have been described and each has a characteristic geographic distribution and a distinct clinical course. HDV and HBV coinfection can be associated with complex and dynamic viral dominance patterns. Chronic HDV infection leads to more severe liver disease than HBV monoinfection and is associated with accelerated fibrosis progression, earlier hepatic decompensation and an increased risk for the development of hepatocellular carcinoma. So far, only IFN-alpha treatment has proven antiviral activity against HDV in humans and has been linked to improved long-term outcomes. Studies conducted in the past 2 years on the use of PEG-IFN-alpha show that a sustained virologic response to therapy, measured in terms of undetectable serum HDV RNA levels, can be achieved in about one quarter of patients with hepatitis D. Novel alternative treatment options including prenylation inhibitors are awaiting clinical development for use in hepatitis D.
Similar articles
- Hepatitis delta: immunopathogenesis and clinical challenges.
Grabowski J, Wedemeyer H. Grabowski J, et al. Dig Dis. 2010;28(1):133-8. doi: 10.1159/000282076. Epub 2010 May 7. Dig Dis. 2010. PMID: 20460901 Review. - An update on HDV: virology, pathogenesis and treatment.
Alvarado-Mora MV, Locarnini S, Rizzetto M, Pinho JR. Alvarado-Mora MV, et al. Antivir Ther. 2013;18(3 Pt B):541-8. doi: 10.3851/IMP2598. Epub 2013 Jun 21. Antivir Ther. 2013. PMID: 23792471 Review. - Hepatitis D revival.
Wedemeyer H. Wedemeyer H. Liver Int. 2011 Jan;31 Suppl 1:140-4. doi: 10.1111/j.1478-3231.2010.02408.x. Liver Int. 2011. PMID: 21205152 Review. - Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, Arseniou V, Manolakopoulos S, Hadziyannis ES, Gault E, Koskinas J, Papatheodoridis G, Archimandritis AJ. Manesis EK, et al. Antivir Ther. 2007;12(3):381-8. Antivir Ther. 2007. PMID: 17591028 - Short article: Hepatitis delta in patients with resolved hepatitis B virus infection.
Aguilera A, Rodríguez-Calviño J, de Mendoza C, Soriano V. Aguilera A, et al. Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1063-1065. doi: 10.1097/MEG.0000000000001187. Eur J Gastroenterol Hepatol. 2018. PMID: 29927770
Cited by
- Dynamics of Virological and Clinical Response Parameters of Bulevirtide Treatment for Hepatitis D: Real-World Data.
Killer A, Gliga S, Lohr C, Weigel C, Ole Jensen BE, Lübke N, Walker A, Timm J, Bode J, Luedde T, Bock HH. Killer A, et al. Gastro Hep Adv. 2024 Jan 5;3(3):353-360. doi: 10.1016/j.gastha.2024.01.001. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39131142 Free PMC article. - Prevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study.
Schinas G, Antonopoulou N, Vamvakopoulou S, Tsachouridou O, Protopapas K, Petrakis V, Petrakis EC, Papageorgiou D, Metallidis S, Papadopoulos A, Barbounakis E, Kofteridis D, Panagopoulos P, Lekkou A, Paliogianni F, Akinosoglou K. Schinas G, et al. Viruses. 2024 Jun 28;16(7):1044. doi: 10.3390/v16071044. Viruses. 2024. PMID: 39066206 Free PMC article. - Viral hepatitis-induced acute liver failure.
Biswas S, Kumar R, Shalimar, Acharya SK. Biswas S, et al. Indian J Gastroenterol. 2024 Apr;43(2):312-324. doi: 10.1007/s12664-024-01538-w. Epub 2024 Mar 7. Indian J Gastroenterol. 2024. PMID: 38451383 Review. - Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma.
Xu L, Xu Y, Zhang F, Xu P, Wang L. Xu L, et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Jan 19;53(1):64-72. doi: 10.3724/zdxbyxb-2023-0481. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024. PMID: 38426692 Free PMC article. Review. Chinese, English. - Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.
Shekhtman L, Cotler SJ, Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Facchetti F, Ceriotti F, Lampertico P, Dahari H. Shekhtman L, et al. JHEP Rep. 2023 Nov 15;6(2):100966. doi: 10.1016/j.jhepr.2023.100966. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38274491 Free PMC article.
References
- Acta Gastroenterol Belg. 2000 Apr-Jun;63(2):221-4 - PubMed
- Virology. 2006 Jan 5;344(1):71-6 - PubMed
- Liver Int. 2010 Mar;30(3):430-7 - PubMed
- J Hepatol. 1990 Jan;10(1):77-84 - PubMed
- Gastroenterology. 2006 May;130(6):1625-35 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous